On 14 June 2007, orphan designation (EU/3/07/452) was granted by the European Commission to Trio Medicines Ltd, United Kingdom, for R-1-[2,3-dihydro-2-oxo-1-pivaloylmethyl-5-(2-pyridyl)-1 H-1,4-benzodiazepin-3-yl]-3-(3-methylaminophenyl)urea for the treatment of gastric carcinoid.

The sponsorship was transferred to Regulis Consulting Europe Limited, Ireland, in April 2019.

Key facts

Active substance
R-1-[2,3-dihydro-2-oxo-1-pivaloylmethyl-5-(2-pyridyl)-1 H-1,4-benzodiazepin-3-yl]-3-(3-methylaminophenyl)urea (netazepide)
Disease / condition
Treatment of gastric carcinoid
Date of first decision
EU designation number

Review of designation

This medicine is now known as netazepide.

Sponsor's contact details

Regulis Consulting Europe Limited
The Black Church
Saint Mary's Place
Dublin 7 DO7 P4AX
Tel: +353 1 231 4691

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;

How useful was this page?

Add your rating